Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study

• DOI: 10.7554/elife.91737
• Publication Date: 2023-12-22T10:15:06Z
• Authors: Guanglei Chen; Xi Gu; Jinqi Xue; Xu Zhang; Xiaopeng Yu; Yu Zhang; Ailin Li; Yi Zhao; Guijin He; Meiyue Tang; Fei Xing; Jianqiao Yin; Xiaobo Bian; Ye Han; Shuo Cao; Chao Liu; Xiaofan Jiang; Keliang Zhang; Yan Xia; Huajun Li; Nan Niu; Caigang Liu
• Keywords: Triple-negative breast cancer; Carboplatin; Clinical endpoint; Neoadjuvant Therapy

Background: Emerging data have supported the immunostimulatory role of radiotherapy, which could exert a synergistic effect with immune checkpoint inhibitors (ICIs). With proven effective but suboptimal ICI and chemotherapy in triple-negative breast cancer (TNBC), we designed pilot study to explore efficacy safety neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab TNBC patients. Methods: Treatment-naïve patients received two cycles intravenous (20 mg/kg, every 3 weeks), SBRT (24 Gy/3 f, other day) started at second cycle, then followed by six nab-paclitaxel (125 mg/m² on days 1 8) carboplatin (area under curve 6 mg/mL per min day 1) weeks. The surgery was performed within 3–5 weeks after end therapy. Primary endpoint pathological complete response (pCR, ypT0/is ypN0). Secondary endpoints included objective rate (ORR), residual burden (RCB) 0-I, safety. Results: 13 were enrolled least one dose 10 (76.9%) completed analysis. 90% (9/10) achieved pCR, both RCB 0-I ORR reached 100% three remission. Adverse events (AEs) all-grade grade 3–4 occurred 92.3% 53.8%, respectively. One (7.7%) patient had treatment-related serious AEs. No radiation-related dermatitis or death occurred. Conclusions: Adding led substantial proportion pCR acceptable toxicities, supporting further exploration this combination Funding: None. Clinical trial number: NCT05132790 .